The impact of metabolic dysfunction-associated steatotic liver disease on non-invasive fibrosis scores in patients with chronic hepatitis B: a multicenter retrospective study Authors: Yakup Gezer, Muhammet Rıdvan Tayşi, Arzu Tarakçı, Sevil Alkan, Selçuk Kaya, Zeynep Çelik, Sevgi Alan Doğan, Emre Bayhan, Selcen Özer Kökkızıl, Derya Tumer, Ahmet Doğan, Tuğba Demircioğlu, Oğuz Evlice, Ahmet Basutçu, Zeynep Burçin Yılmaz, Funda Memişoğlu, Ekrem Salduz, Esra Sağlam Kandemir, Mustafa Yüksel, Ethem Ömeroğlu Published: 2026 ABSTRACT AbstractBackgroundThe coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic hepatitis B (CHB) may influence liver fibrosis, but the relationship between these conditions remains unclear. MASLD may also affect the performance of non-invasive tests (NITs) in CHB. Recently developed NITs, such as FIB-8 and FIB-9, were designed for MASLD patients but have not been assessed in those with both CHB and MASLD. This study aimed to comparatively assess the diagnostic performance of various NITs for predicting significant fibrosis in CHB patients stratified by MASLD status.MethodsIn this multicenter retrospective study, CHB patients who underwent liver biopsy were analyzed. Significant fibrosis was defined as ISHAK stage ≥ 3, and hepatic steatosis as ≥ 5% fat accumulation on biopsy. The performance of 20 NITs in predicting significant fibrosis was assessed in the overall cohort and in MASLD-positive and MASLD negative groups.ResultsA total of 1545 patients were included, of whom 328 (21.2%) were MASLD-positive. More than half of the MASLD-positive patients had a single cardiometabolic risk factor. In the MASLD-negative group, FIB-4 showed the highest area under the receiver operating characteristic curve (AUROC) value (0.660), whereas in the MASLD-positive group, the highest AUROC was observed for FIB-8 (0.728). Furthermore, the FIB-8, Lok, and ATA scores demonstrated significantly higher AUROC values in the MASLD-positive group than in the MASLD-negative group (0.728, 0.726, and 0.716 vs. 0.535, 0.590, and 0.600, respectively; p = 0.008, 0.002, and 0.008). No significant differences were observed in the performance of the remaining NITs according to MASLD status.ConclusionsThe diagnostic performance of NITs for predicting significant fibrosis in CHB patients varies according to MASLD status. FIB-8, Lok, and ATA scores demonstrated significantly higher diagnostic accuracy in MASLD-positive patients, suggesting that metabolic factors may influence the discriminative capacity of fibrosis markers. Nevertheless, all evaluated NITs demonstrated low-to-moderate diagnostic performance across all groups, limiting their standalone clinical utility and highlighting the need for more accurate non-invasive fibrosis models in this population.Trial registrationNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12876-026-04959-3.Keywords: Fibrosis-4, FIB-8, Steatotic liver disease, Hepatitis B virus, Non-invasive test Background According to the World Health Organization (WHO), nearly 254 million people worldwide were affected by chronic hepatitis B (CHB) in 2022, highlighting its continued significance as a public health issue. Its prevalence varies geographically, ranging from 0.5% in the Americas to as high as 5.8% in Africa [1]. In Türkiye, the prevalence of hepatitis B surface antigen (HBsAg) positivity is estimated at approximately 4%, placing the country in the intermediate endemicity category [2]. Assessment of liver fibrosis is essential for treatment planning and prognosis estimation in patients with CHB. Percutaneous liver biopsy continues to serve as the benchmark for histological assessment; however, because it is invasive, its use is impractical for regular screening or follow-up. Consequently, non-invasive tests (NITs) have become increasingly popular due to their simplicity, rapid calculation, and non-invasive characteristics. The WHO recommends serum biomarker-based indices—such as the aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) score—as viable alternatives to liver biopsy [3]. Furthermore, an expanding array of non-invasive diagnostic tools has been introduced to accurately assess and predict the degree of liver fibrosis. Metabolic dysfunction-associated steatotic liver disease (MASLD) was redefined in 2023 as hepatic steatosis occurring with one or more cardiometabolic risk factors (CMRFs) [4]. Currently affecting more than 30% of the adult population, MASLD is considered the predominant cause of chronic liver disease on a global scale [5]. The relationship between MASLD and CHB is complex and remains incompletely understood. While some studies suggest that the presence of MASLD may increase the risk of fibrosis progression in patients with CHB, others have reported no significant association between the two conditions indicating that the clinical consequences of their coexistence remain a matter of debate [6–8]. Following the introduction of the MASLD terminology, it has been increasingly recognized that the performance of NITs used for fibrosis assessment may vary according to metabolic status [9]. However, most studies evaluating NIT performance in CHB patients have not accounted for the presence of MASLD, and it remains unclear which test provides the highest diagnostic accuracy in this subgroup. Moreover, the diagnostic performance of commonly used scores such as APRI and FIB-4 may be reduced in the presence of MASLD [8]. These observations highlight the need for a broader evaluation using a panel of non-invasive tests incorporating diverse biochemical and clinical parameters. The aim of this study was to comparatively evaluate the diagnostic performance of multiple non-invasive tests for predicting significant fibrosis in CHB patients stratified according to MASLD status. Methods Study design and patient selection The study was designed as a retrospective, multicenter investigation that included adult CHB patients (≥ 18 years) who were followed by infectious diseases and clinical microbiology departments at ten different hospitals in Türkiye (three secondary-level and seven tertiary-level centers), between January 2014 and December 2024. Patients were eligible if they had undergone histological assessment via liver biopsy and had not received antiviral therapy for CHB prior to the biopsy. In Türkiye, the management of CHB is conducted within the framework of the national health insurance system, where reimbursement for antiviral therapy is contingent upon an HBV DNA level ≥ 2000 IU/mL together with histological evidence of liver fibrosis. Accordingly, liver biopsy is routinely performed in clinical practice—particularly in patients with HBV DNA levels ≥ 2000 IU/mL—to determine treatment eligibility. Patients were excluded if they met any of the following criteria: coinfection with hepatitis C virus (HCV) or hepatitis D virus (HDV); diagnosis of human immunodeficiency virus (HIV); presence of hepatocellular carcinoma (HCC) or any other malignancy; diagnosis of alcoholic hepatitis; excessive alcohol intake (defined as more than 30 g per day in men and more than 20 g per day in women); autoimmune hepatitis; other chronic liver diseases; or a history of hepatotoxic drug use (Fig. 1). The STROBE flow chart of the study, * MASLD, metabolic dysfunction-associated steatotic liver disease; HCC, hepatocellular carcinoma; HDV, hepatitis D virus This study was designed and reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines to ensure transparency and completeness in reporting observational research. Definitions CHB was defined as the persistence of hepatitis B surface antigen (HBsAg) positivity for more than six months. Significant fibrosis was defined as stage ≥F3 according to the ISHAK scoring system. MASLD was diagnosed when hepatic steatosis was present along with at least one CMRF: body mass index (BMI) ≥ 25 kg/m²; presence prediabetes or diabetes mellitus (DM) or treatment for DM; use of antihypertensive medication or blood pressure ≥ 130/85 mmHg; HDL level < 40 mg/dL in men and < 50 mg/dL in women, or use of lipid-lowering therapy; and triglyceride level ≥ 150 mg/dL or use of lipid-lowering therapy [4]. Hepatic steatosis was defined histopathologically as the presence of ≥ 5% hepatic fat content. Data collection Demographic and clinical data—including age, sex, BMI, blood pressure, alcohol consumption, comorbidities, and laboratory parameters [platelet count (PLT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), prothrombin time (PT), international normalized ratio (INR), blood urea nitrogen (BUN), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, alpha-fetoprotein (AFP), albumin (ALB), HBV DNA levels, HBsAg, and hepatitis B e antigen (HBeAg)]—as well as liver histopathological findings were retrospectively retrieved from electronic medical records. Laboratory parameters were measured at each center using standard automated methods. HBV DNA levels were quantified and HBsAg and HBeAg were determined using commercially available real-time polymerase chain reaction and chemiluminescent immunoassay platforms, respectively. Liver biopsy was performed under ultrasound guidance via a 16-gauge needle. Only specimens that were adequate (containing at least six portal tracts and measuring at least 10 mm in length) were included. The samples were fixed in 10% formalin, embedded in paraffin wax and stained with hematoxylin and eosin. The biopsy materials were also stained via Masson’s trichrome and reticular fiber stains. Liver fibrosis staging was performed by pathologists at the study centers without knowledge of the clinical outcomes. Histopathological evaluation of the liver samples was performed using the ISHAK scoring system, with fibrosis stages ranging from F0 to F6 [10]. Laboratory parameters obtained within two weeks prior to liver biopsy were included in the analysis. The upper limit of normal (ULN) for ALT and AST was defined as 40 U/L, in accordance with the guidelines of the European Association for the Study of the Liver (EASL) [11]. A total of 20 NITs were calculated for each patient using available laboratory and clinical data. These tests were selected to enable a comprehensive comparative evaluation encompassing scores based on diverse biochemical and clinical parameters. The formula for each score is provided in the Supplementary Material (Table S1) [12–30]. Statistical analysis Statistical analyses were conducted using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). The Shapiro–Wilk test was applied to assess the distribution of continuous variables. Variables not following a normal distribution were summarized as medians with interquartile ranges (IQR, 25th–75th percentile), and comparisons between groups were made using the Mann–Whitney U test. Categorical data were expressed as counts and percentages, and differences across groups were evaluated using the chi-square test. The diagnostic performance of NITs in predicting significant fibrosis was examined through the area under the receiver operating characteristic curve (AUROC). The cut-off values were calculated by maximizing the Youden index to evaluate the diagnostic efficacy of NITs. The following performance metrics were computed: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy. ROC curves and corresponding AUROC values were generated separately for MASLD-positive and MASLD-negative groups. Differences in AUROC between MASLD-positive and MASLD-negative groups were evaluated using a non-parametric z-test for independent samples (DeLong’s test). Results were reported with corresponding confidence intervals and standard errors to reflect statistical uncertainty. Due to missing biochemical data, some NITs could not be calculated in all patients. These patients were excluded only from the specific analyses related to the missing NIT but were retained in other analyses. The number of patients excluded from each NIT analysis is indicated in the corresponding table footnotes. Multivariable logistic regression analysis was performed to identify independent predictors of significant fibrosis. Clinically relevant variables were included in the model, and adjusted odds ratios (aORs) with 95% confidence intervals were reported. Model fit and multicollinearity were assessed prior to final interpretation. Given the retrospective design, no a priori sample size or power calculation was performed; all eligible patients during the study period were included. Statistical significance was defined as a p-value less than 0.05 throughout the analyses. Results Study population and patient characteristics Based on the inclusion criteria, a total of 1,884 CHB patients were identified. After applying the exclusion criteria, 1545 patients were included in the final analysis (Fig. 1). The median age was 46 years (IQR 36–56), and 55.1% of the patients were male. Hepatic steatosis was present in 30.1% of patients, DM in 9.1%, hypertension (HT) in 9.5%, and dyslipidemia in 15.8%. The median BMI was 26.1 (IQR 23.2–29.4). HBeAg positivity was detected in 14.1% of patients, and significant fibrosis was present in 18.1%. 328 patients (21.2%) were MASLD-positive. Of the MASLD-positive patients, 57.6% had one, 23.2% had two, and 19.2% had three or more CMRFs. Compared to MASLD-negative patients, the MASLD-positive group had significantly higher median values for age, BMI, platelet count, BUN, AST, ALT, ALP, and GGT (p < 0.05). In contrast, median AFP levels and the proportion of HBeAg positivity were significantly higher in the MASLD-negative group (p < 0.001 and p = 0.004, respectively) (Table 1). Table 1Basic demographic characteristics and laboratory dataVariableTotal*(n = 1545)MASLD (-) group* (n = 1217)MASLD (+) group* (n = 328)p value**Age, years46 (36–56)44 (35–55)51 (43–60)< 0.001Male Sex851 (55.1%)665 (54.6%)186 (56.7%)0.505BMI, kg/m226.1 (23.2–29.4)24.4 (22.2–27.1)29.5 (27.8–32.1)< 0.001Hepatic steatosis a465 (30.1%)137 (11.3%)328 (100.0%)< 0.001Diabetes mellitus141 (9.1%)71 (5.8%)70 (21.3%)< 0.001Hypertension146 (9.5%)79 (6.5%)67 (20.4%)< 0.001Dislipidemia244 (15.8%)115 (9.5%)129 (39.3%)< 0.001HBeAg positivity218 (14.1%)188 (15.4%)30 (9.1%)0.004Platelet count,109/L232 (190–274)230 (188–270)239.5 (201–294)0.001INR1.00 (0.96–1.10)1.01 (0.98–1.10)1.00 (0.90–1.08)< 0.001BUN23 (15–33)22 (14–32)27 (16–36)< 0.001AST, IU/L29.1 (21-42.9)28 (20-41.2)34.9 (23.7–45.2)0.003ALT, IU/L45 (23–80)40 (22-75.3)67.5 (34-88.9)< 0.001ALP, IU/L79 (64–98)78 (64–95)86 (66–100)0.005GGT, IU/L28 (17–44)25 (16–41)37.5 (22–66)< 0.001AFP2 (1.2–3.1)2.2 (1.3–3.3)1.7 (1-2.58)< 0.001Albumin, g/L42 (39–45)42 (39.5–45)42 (39–45)0.116HBV DNA, log10 IU/mL5.3 (4.2–6.1)5.3 (4.2–6.3)5.3 (4.4–5.7)0.788Significant fibrosis (F ≥ 3)279 (18.1%)233 (19.1%)46 (14.0%)0.032The extent of missing data varied across variables: BMI was unavailable in 668 patients; platelet count in 15; INR in 30; BUN in 89; AST in 15; ALT in 13; ALP in 327; GGT in 318; AFP in 80; albumin in 231; and HBV DNA in 11 patientsa Hepatic steatosis was defined histopathologically as the presence of ≥ 5% hepatic fat content*Numerical variables were shown as median (IQR 25%-75%); categorical variables were expressed as number (%)**Numerical data: Mann–Whitney U Test; categorical data: Chi-Square TestBMI Body mass index, HBeAg Hepatitis B early antigen, INR International normalized ratio, BUN Blood urea nitrogen, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ALP Alkaline phosphatase, GGT Gamma-glutamyltransferase, AFP Alpha fetoprotein, F Fibrosis stage, MASLD Metabolic dysfunction-associated steatotic liver disease Basic demographic characteristics and laboratory data The extent of missing data varied across variables: BMI was unavailable in 668 patients; platelet count in 15; INR in 30; BUN in 89; AST in 15; ALT in 13; ALP in 327; GGT in 318; AFP in 80; albumin in 231; and HBV DNA in 11 patients a Hepatic steatosis was defined histopathologically as the presence of ≥ 5% hepatic fat content *Numerical variables were shown as median (IQR 25%-75%); categorical variables were expressed as number (%) **Numerical data: Mann–Whitney U Test; categorical data: Chi-Square Test BMI Body mass index, HBeAg Hepatitis B early antigen, INR International normalized ratio, BUN Blood urea nitrogen, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ALP Alkaline phosphatase, GGT Gamma-glutamyltransferase, AFP Alpha fetoprotein, F Fibrosis stage, MASLD Metabolic dysfunction-associated steatotic liver disease The prevalence of significant fibrosis (F ≥ 3) was lower in the MASLD-positive group (p = 0.032) (Table 1). Among MASLD-positive patients, significant fibrosis was found in 11.6% (22/189) of those with one CMRF, 17.1% (13/76) of those with two CMRFs, and 17.5% (11/63) of those with three or more CMRFs. Nevertheless, these differences did not reach statistical significance (p = 0.349) (data not shown). Multivariable logistic regression analysis was performed to identify independent predictors of significant fibrosis. Male sex (OR: 1.43; 95% CI: 1.09–1.88; p = 0.011), older age (OR: 1.03; 95% CI: 1.02–1.04; p < 0.001), and higher HBV DNA levels (log₁₀ IU/mL) (OR: 1.24; 95% CI: 1.11–1.38; p < 0.001) were independently associated with an increased risk of significant fibrosis. In contrast, the presence of MASLD was associated with a lower likelihood of significant fibrosis (OR: 0.57; 95% CI: 0.40–0.82; p = 0.002). No significant associations were observed between significant fibrosis and HBeAg positivity (p = 0.633) or ALT levels (p = 0.655) (Table 2). Table 2Univariate analysis and Multivariate analysis of independent predictors of significant fibrosis in patients with CHBVariablesUnivariate analysisMultivariate analysisOR (95%CI)P valueOR (95%CI)P valueAge, years1.019 (1.009–1.029)< 0.0011.026 (1.016–1.037)< 0.001Male Sex1.390 (1.066–1.812)0.0151.431 (1.087–1.884)0.011MASLD presence0.689 (0.489–0.971)0.0330.567 (0.395–0.815)0.002ALT, IU/L1.003 (0.999–1.006)0.1090.999 (0.995–1.003)0.655HBeAg positivity1.215 (0. 850-1.736)0.2850.899 (0.581–1.391)0.633HBV DNA, log10 IU/mL1.174 (1.080–1.277)< 0.0011.236 (1.106–1.380)< 0.001*MASLD Metabolic dysfunction-associated steatotic liver disease, ALT Alanine aminotransferase, HBeAg Hepatitis B early antigen, HBV DNA Hepatitis B virus deoxyribonucleic acid, CHB Chronic hepatitis B Univariate analysis and Multivariate analysis of independent predictors of significant fibrosis in patients with CHB *MASLD Metabolic dysfunction-associated steatotic liver disease, ALT Alanine aminotransferase, HBeAg Hepatitis B early antigen, HBV DNA Hepatitis B virus deoxyribonucleic acid, CHB Chronic hepatitis B Performance evaluation of non-invasive fibrosis tests The diagnostic performance of 20 NITs in detecting significant fibrosis was assessed by calculating AUROC values across the overall cohort, as well as in MASLD-negative and MASLD-positive groups. FIB-4 demonstrated the highest AUROC in both the overall cohort and the MASLD-negative group (0.656 and 0.660, respectively), whereas FIB-8 yielded the highest AUROC in the MASLD-positive group (0.728) (Tables S2–S4). In the MASLD-negative group, FIB-4 (cut-off: 0.996) showed a sensitivity of 60% and a specificity of 66% (Table S3). In the MASLD-positive group, FIB-8 (cut-off: 1.728) achieved a sensitivity of 67% and a specificity of 77% (Table S4). The AUROC values of the FIB-8, Lok, and ATA scores were 0.535, 0.590, and 0.600, respectively, in the MASLD-negative group, and 0.728, 0.726, and 0.716, respectively, in the MASLD-positive group. A significant difference was observed between the two groups (p = 0.008, 0.002, and 0.008, respectively) (Fig. 2). The AUROC values of the other NITs did not differ significantly between the two groups (Table 3). ROC Curve Analyses Comparing Non-Invasive Tests in CHB Patients According to MASLD Status: A: FIB-8; B: ATA; C: Lok, *CHB, chronic hepatitis B; MASLD, metabolic dysfunction-associated steatotic liver disease Table 3Comparison of the diagnostic performance of NITs in predicting significant fibrosis in CHB patients with and without MASLDScoresMASLD (-)MASLD (+)AUROC DifferenceP valueAUROC95% CISEAUROC95% CISEFIB-40.660.621–0.6990.020.650.566–0.7340.0430.010.840AGAP0.6030.555–0.6500.0240.6140.521–0.7080.0480.0120.825APGA0.6170.569–0.6660.0250.6360.529–0.7420.0540.0180.761API0.6130.573–0.6530.020.6080.522–0.6940.0440.0040.926King’s0.6480.609–0.6880.020.6610.566–0.7560.0490.0130.810ATA index0.600.555–0.6460.0230.7160.644–0.7880.0370.116 0.008 APRI0.6320.593–0.6720.020.6150.513–0.7180.0520.0170.761GUCI0.6290.589–0.6700.0210.6450.541–0.7490.0530.0150.787FibroQ0.6210.581–0.6610.020.680.603–0.7570.0390.0590.184FIB-50.6110.563–0.6590.0240.650.570–0.7290.0410.0380.422GPR0.5710.524–0.6180.0240.5470.461–0.6330.0440.0240.628Fibro-Alpha0.6120.571–0.6530.0210.6440.561–0.7280.0420.0330.488FI0.5850.539–0.6310.0230.6320.553–0.7110.0400.0470.312NFS0.5960.522–0.6700.0380.6550.556–0.7540.0500.0590.346S index0.5670.519–0.6140.0240.5660.481–0.6520.0440.0010.996Lok0.590.547–0.6320.0220.7260.653–0.8000.0370.137 0.002 FCI0.5530.504–0.6030.0250.5520.457–0.6470.0490.0010.985FIB-80.5350.446–0.6250.0460.7280.618–0.8380.0560.193 0.008 FIB-90.5110.421–0.6010.0460.6280.508–0.7470.0610.1170.126FIB-60.5930.545–0.6400.0240.6710.586–0.7550.0430.0780.114*MASLD Metabolic dysfunction-associated steatotic liver disease, AUROC Area under the ROC curve, SE Standard error, APRI Aspartate aminotransferase to platelet ratio index, FIB-4 Fibrosis-4, GPR Gamma‐glutamyl transpeptidase to platelet ratio, NFS Nonalcoholic fatty liver disease fibrosis score, GUCI Goteborg University Cirrhosis Index, FI Fibrosis index, FCI Fibrosis cirrhosis index, FibroQ Fibroquotient, API Age-platelet index, APGA index AST/platelet/GGT/AFP index Comparison of the diagnostic performance of NITs in predicting significant fibrosis in CHB patients with and without MASLD *MASLD Metabolic dysfunction-associated steatotic liver disease, AUROC Area under the ROC curve, SE Standard error, APRI Aspartate aminotransferase to platelet ratio index, FIB-4 Fibrosis-4, GPR Gamma‐glutamyl transpeptidase to platelet ratio, NFS Nonalcoholic fatty liver disease fibrosis score, GUCI Goteborg University Cirrhosis Index, FI Fibrosis index, FCI Fibrosis cirrhosis index, FibroQ Fibroquotient, API Age-platelet index, APGA index AST/platelet/GGT/AFP index The diagnostic performance of APRI was evaluated using different cut-off values in MASLD-negative and MASLD-positive groups. In the MASLD-negative group, at a cut-off value of 0.5, sensitivity was 35.2%, specificity 79.5%, positive predictive value (PPV) 29.0%, and negative predictive value (NPV) 83.8%. When a lower cut-off value of 0.328 was applied, sensitivity increased to 66%, while specificity decreased to 56%; PPV remained similar, and NPV improved to 87%. In the MASLD-positive group, at a cut-off value of 0.5, sensitivity was 45.7%, specificity 77.7%, PPV 25.0%, and NPV 89.8%. At a higher cut-off value of 0.625, specificity increased to 88%, while sensitivity decreased to 39%, and NPV slightly increased to 90%. Discussion In this study, the FIB-8 score demonstrated the highest diagnostic accuracy in CHB patients with MASLD, whereas FIB-4 performed best in the overall cohort and in MASLD-negative patients. Moreover, the significantly higher performance of FIB-8, Lok, and ATA scores in the MASLD-positive group suggests that the metabolic background may influence the diagnostic accuracy of certain non-invasive tests. Nevertheless, the overall low-to-moderate AUROC values across all NITs indicate that their standalone use in clinical decision-making remains limited. Since the redefinition of MASLD in 2023, studies have reported a prevalence ranging from 14% to 53.6% among patients with CHB [8, 31, 32]. The prevalence observed in our cohort (21.2%) is consistent with these previous findings. In our study, MASLD was defined histologically, allowing for a more objective assessment of hepatic steatosis. However, this approach may limit generalizability to populations defined by imaging-based criteria. Although the inclusion of only biopsied patients may reflect a selected cohort, the use of liver biopsy as the reference standard strengthens the validity of NIT comparisons. Furthermore, biopsy indications based on national reimbursement criteria and the consecutive inclusion of patients likely mitigated selection bias and enhanced the clinical representativeness of the dataset. Despite older age and higher ALT levels, the lower prevalence of significant fibrosis in MASLD-positive patients suggests a dissociation between inflammation and fibrogenesis [33, 34]. While ALT reflects hepatocellular injury, fibrosis represents cumulative and chronic liver damage. In MASLD, lipotoxicity and oxidative stress tend to emerge early, whereas fibrosis may develop later [7, 35]. Accordingly, the elevated ALT levels observed in the MASLD-positive group may primarily reflect early metabolic inflammation rather than established fibrosis. Conversely, the higher AFP levels and greater fibrosis burden in the MASLD-negative group point toward a more prominent HBV-driven fibrogenic process. However, AFP alone is not considered a reliable marker for fibrosis prediction [36, 37]. Likewise, although HBeAg reflects viral replication status, it does not reliably reflect fibrosis burden, particularly in the presence of metabolic conditions such as MASLD. Moreover, the well-recognized biochemical and virological overlap between different phases of HBV infection, with a substantial proportion of patients residing in a heterogeneous “grey zone,” further underscores that biochemical markers do not always reliably reflect fibrosis severity [11, 38]. These findings support our observation that, particularly in the presence of MASLD, inflammatory activity may influence biochemical parameters independently of fibrosis. In multivariable analysis, male sex, older age, and higher HBV DNA levels were identified as independent predictors of significant fibrosis, consistent with prior studies in CHB populations [32, 39, 40]. In contrast, the presence of MASLD was inversely associated with significant fibrosis, in line with studies reporting a negative association between MASLD and fibrosis in CHB [41]. However, the literature remains inconsistent, with conflicting results across studies [8, 31, 32]. This heterogeneity may reflect differences in the metabolic spectrum of MASLD, methodological approaches, and patient characteristics. The literature provides conflicting evidence regarding whether MASLD influences the performance of NITs in patients with CHB. In a retrospective study, Con et al. reported that the accuracy of APRI and FIB-4 scores may decrease in the presence of MASLD [8]. Conversely, Lin et al. demonstrated that the diagnostic performance of APRI and FIB-4 was comparable between CHB patients with and without hepatic steatosis [42]. Furthermore, Chen et al. emphasised that although the overall diagnostic accuracy of FIB-4, APRI, and GPR remains preserved in CHB patients assessed under different definitions of steatotic liver disease — including NAFLD, MASLD, metabolic-associated fatty liver disease (MAFLD) and metabolic- and alcohol-related liver disease (MetALD) — the optimal cut-off points may vary [43]. These findings suggest that variability in NIT performance may be driven by the heterogeneous pathophysiology of MASLD. Metabolic inflammation may alter AST and ALT levels independently of fibrosis, thereby affecting the accuracy of biochemical-based scores [9]. In our study, subgroup-specific cut-off variability supports this notion. However, aside from FIB-8, Lok, and ATA, the overall performance of most NITs remained comparable across groups, reinforcing the notion that their diagnostic limitations persist regardless of MASLD status. The variability in APRI cut-off values observed in our study significantly influenced diagnostic performance in both MASLD-negative and MASLD-positive groups. Lower thresholds increased sensitivity at the expense of specificity, whereas higher thresholds demonstrated the opposite pattern. Importantly, this finding is not unique to APRI but reflects a broader characteristic of biochemical-based NITs, suggesting that optimal cut-off values may shift in the presence of MASLD. Therefore, cut-off selection should be tailored to the intended clinical purpose (screening vs. confirmation). Cales et al. introduced the FIB-8 and FIB-9 scores using a multi-target machine learning approach and demonstrated improved performance over FIB-4 in MASLD populations [12]. In our study, these novel tests were evaluated in CHB patients stratified according to MASLD status. However, direct comparative data on this specific population remain limited, particularly for recently developed scores such as FIB-8 and FIB-9. FIB-8 achieved the highest diagnostic accuracy in MASLD-positive patients, with Lok and ATA scores showing similar trends. However, the clinical relevance of these performance differences remains to be fully established. An examination of the shared components of FIB-8, Lok, and ATA scores reveals the inclusion of parameters such as platelet count, INR/PT, and AST, with some also incorporating albumin. These biomarkers, which reflect hepatic synthetic function, may more accurately capture the underlying fibrotic process developing within the metabolic environment of MASLD. This may partly explain their relatively better performance in MASLD-positive patients. When MASLD-specific cut-off values were applied, the FIB-8 and Lok scores demonstrated a balanced sensitivity–specificity profile, whereas the ATA index showed high sensitivity but low specificity. This suggests that the ATA index may be more suitable as a screening tool for fibrosis, while requiring confirmation with additional tests in diagnostic settings. Nevertheless, these findings should be interpreted with caution, as optimal cut-off values may vary across different populations and require validation in large-scale studies. Taken together, the overall diagnostic performance of currently available NITs for fibrosis assessment in CHB patients ranges from low to moderate, highlighting their limitations when used as standalone tools in clinical decision-making. In contrast, the relatively higher performance of the FIB-8, ATA, and Lok indices in MASLD-positive CHB patients suggests that these scores may represent more appropriate alternatives within this subgroup. However, the consistently limited discriminative ability observed across all NITs underscores the need for the development of next-generation models that provide greater diagnostic accuracy and better reflect patient heterogeneity. The present study has several notable strengths. In particular, it represents one of the first comprehensive multicenter investigations to evaluate the diagnostic performance of a broad panel of non-invasive tests, including the recently developed FIB-8 and FIB-9 scores, in a large CHB cohort stratified by MASLD status. The study was designed to evaluate the impact of MASLD on NIT performance within a CHB cohort; therefore, a separate control group consisting of patients with MASLD alone was not included. This represents a limitation in terms of directly benchmarking MASLD-specific scores against populations for which they were originally developed. Future prospective studies incorporating both CHB-only and MASLD-only cohorts would enable a more comprehensive evaluation of these scores across different disease contexts. Limitations of the study Several limitations of this study should be acknowledged. Due to its retrospective design, complete biochemical data were not available for all patients. Patients with missing data were excluded only from analyses specific to the relevant NIT, but were retained in the evaluation of other tests. The timing between liver biopsy and blood sampling may not have been fully synchronized in all cases. In addition, the lack of a centralized pathological review introduces a risk of interobserver variability. However, the use of the standardized ISHAK scoring system by experienced hepatopathologists partially mitigated this limitation. The inclusion of only biopsy-proven patients limits the generalizability of the findings to the broader CHB population. Differences in group sizes and baseline characteristics between MASLD-positive and MASLD-negative patients may have influenced the statistical power of subgroup analyses and the interpretation of NIT performance. Finally, because the study was designed to evaluate NIT performance in CHB patients stratified according to MASLD status, a separate MASLD-only cohort was not included; this limits the direct comparison of MASLD-specific scores in the originally intended population. Conclusions The findings of this study demonstrated that the FIB-8, Lok, and ATA scores showed significantly higher diagnostic accuracy in the MASLD-positive group. This suggests that metabolic status may influence the performance of certain non-invasive tests. The overall limited diagnostic accuracy of current non-invasive tests restricts their clinical utility in fibrosis assessment. These findings highlight the need for novel multi-parameter models that integrate both viral and metabolic factors to improve non-invasive fibrosis evaluation in clinical practice. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements None. Abbreviations Metabolic dysfunction-associated steatotic liver disease Chronic hepatitis B Noninvasive tests Cardiometabolic risk factor World Health Organization Hepatocellular carcinoma Hepatitis B virus Hepatitis D virus Hepatitis B surface antigen Body mass index Diabetes mellitus Platelet count Asparate aminotransferase Alanine aminotransferase Alkaline phosphatase Gamma-glutamyltransferase Alpha fetoprotein Hepatitis B early antigen Upper limit of normal European Association for the Study of the Liver The area under The Receiver Operating Characteristic curve Authors’ contributions YG and MRT were responsible for the study conception and design. YG and MRT performed the statistical analysis. YG drafted the initial manuscript. Data collection was carried out by all authors. All authors contributed to data interpretation and critically revised the manuscript for important intellectual content. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work. Funding The authors received no funding for the preparation of this work. Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate The study was conducted in accordance with the Declaration of Helsinki and approved by the Non-Interventional Clinical Research Ethics Committee of Konya City Hospital, University of Health Sciences (Approval No: 2025/44 – dated 10.03.2025). The Ethics Committee of Konya City Hospital, University of Health Sciences waived the requirement for participant consent due to the retrospective nature of the study and the use of anonymized data. As part of the consent process, general consent was obtained for the use of medical records in research. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement All data generated or analyzed during this study are included in this published article and its supplementary information files.